Farmaceuten geven maar paar ziekten in arme landen topprioriteit

NOS reports on the 2018 Index highlighting the five companies that are conducting R&D for diseases listed as global priorities. The article also describes company activity in the key areas for access including licensing and pricing and comments on the inclusion of cancer in the Index for the first time.